马德里格尔制药 MDGL

Mr. William John Sibold, President and Chief Executive Officer of Madrigal since September 2023. Possesses more than 30 years of experience in the biopharmaceutical industry. Executive Vice President, Specialty Care of Sanofi, a global pharmaceutical company, and President, Sanofi North America, where he led a global organization of approximately 10,000 employees across five specialty therapeutic areas and served as a member of the Sanofi Executive Committee, from 2017 to September 2023. Senior Vice President, Global Franchise Head, Multiple Sclerosis, Oncology & Immunology, Sanofi Genzyme, from 2016 to 2017. Global Franchise Head Multiple Sclerosis of Sanofi Specialty Care from 2011 to 2016. Chief Commercial Officer of Avanir Pharmaceuticals, Inc. from April 2011 to November 2011. President and CEO of Lycera Corp in 2010. Senior Vice President, U.S. Commercial for Biogen Inc. from 2001 to 2009. Mr. Sibold holds a B.A. in Molecular Biophysics and Biochemistry from Yale University and an M.B.A. from Harvard Business School.

David Soergel, M.D. was appointed as our Chief Medical Officer in April 2025. Prior to joining us, Dr. Soergel served as Executive Vice President and Global Head of Cardiovascular, Renal and Metabolism Development at Novartis, a global pharmaceutical company, from August 2017 until April 2025, where he oversaw ten late-stage development programs in 2024. At Novartis, Dr. Soergel led teams that designed and implemented evidence generation programs supporting the expansion of Entresto's indications and uses. Additionally, Dr. Soergel advanced novel medicines to approval for cardiovascular and renal diseases, including Leqvio, Fabhalta and Vanrafia, and served as the development lead for the acquisitions of the Medicines Company and Chinook Therapeutics, Inc. Prior to Novartis, Dr. Soergel held roles with increasing responsibility at biotechnology companies, including Senior Vice President of Clinical Development and Chief Medical Officer at Trevena, Inc. from March 2015 until August 2017, where he was responsible for the development of novel treatments for pain and other conditions. He began his career in early-stage clinical development and translational medicine at GlaxoSmithKline. Dr. Soergel trained in pediatrics, pediatric cardiology, and heart failure and transplant at Johns Hopkins Hospital and the Children's Hospital of Philadelphia. Dr. Soergel received his B.A. from The Johns Hopkins University and his M.D. from Cornell University Medical College.

Dr. Rebecca A. Taub,M.D., Served as Chief Medical Officer of Madrigal from July 2016 to April 2025 and as President, Research & Development from June 2019 to April 2025 when she transitioned to a Senior Scientific and Medical Advisor role. , Served as Senior Vice President, Research and Development of VIA Pharmaceuticals, Inc. from 2008 to 2011 and Vice President, Research, Metabolic Diseases at F. Hoffmann-La Roche AG from 2004 to 2008 where she oversaw clinical development and drug discovery programs in cardiovascular and metabolic diseases, including the conduct of a series of Phase 1 and 2 proof of concept clinical trials. , Served in various capacities at Bristol-Myers Squibb Company and DuPont from 2000 through 2003, including as Executive Director of central nervous system and metabolic diseases research at each company. , Has authored more than 120 research articles. Tenured Professor of Genetics and Medicine at the University of Pennsylvania from 1987 to 2002, and remains an adjunct professor. , Served as Assistant Professor at the Joslin Diabetes Center of Harvard Medical School, Harvard University and an associate investigator with the Howard Hughes Medical Institute. , Dr. Taub received her M.D. from Yale University School of Medicine and B.A. from Yale College. Dr. Taub has served on the board of directors of BriaCell Therapeutics Corp., Inc. since March 2019.

Mardi Dier has served as our Chief Financial Officer since March 2024. Prior to joining us, Ms. Dier served as the Chief Financial Officer and Chief Business Development Officer at Acelyrin, Inc., a publicly traded biotechnology company, from November 2022 to August 2023 where she completed the company's initial public offering. Prior to joining Acelyrin, Ms. Dier served as the Chief Financial Officer of Ultragenyx Pharmaceutical Inc., a publicly traded biotechnology company, from October 2020 to November 2022 where she led corporate strategy, FP&A, accounting, tax, investor relations, global corporate communications and information technology functions. Ms. Dier joined Ultragenyx from Portola Pharmaceuticals (acquired by Alexion), where she served as Chief Financial Officer for 14 years and, most recently, as Chief Business Officer and Chief Financial Officer. Earlier in her career, Ms. Dier held various roles in investor relations, investment banking and auditing. Ms. Dier has served on the board of directors of ORIC Pharmaceuticals, Inc., a publicly traded company, since February 2020. Ms. Dier previously served as a director of Adamas Pharmaceuticals, Inc. from August 2017 to May 2021 and Prelude from August 2020 to October 2025, each a publicly traded biotechnology company. Ms. Dier received a B.S. in Biology from Stanford University and an M.B.A. from the Anderson Graduate School of Management at the University of California, Los Angeles.

Carole Huntsman was appointed as our Chief Commercial Officer in November 2023. Prior to joining us, Ms. Huntsman was employed by Sanofi, a global pharmaceutical company, from January 2012 to April 2023. At Sanofi, Ms. Huntsman held positions of increasing responsibility, including Head of Multiple Sclerosis, North America, Global Business Unit Head, Multiple Sclerosis, Head of Multiple Sclerosis, Oncology & Immunology Specialty Care North America, and Senior Vice President, Head of Specialty Care North America and Sanofi U.S. Country Lead. Prior to joining Sanofi, during her over 30 years in the biopharmaceutical industry, Ms. Huntsman served as Senior Vice President, U.S. Neurology & Rheumatology at EMD Serono, Inc. (Serono) and Vice President, Marketing U.S. Neurology at Serono, as well as several positions of increasing responsibility at each of Muro Pharmaceuticals and Pfizer Inc. Prior to joining the biopharmaceutical industry, Ms. Huntsman served as an Officer in the U.S. Army. Ms. Huntsman holds a B.A. in History from Boston College and an M.B.A. from The Carroll School, Boston College.

Shannon Kelley was appointed as our Chief Legal Counsel in August 2024. Ms. Kelley has more than 20 years of diverse healthcare experience as a compliance and legal professional. She joined us from Sanofi, where she served in roles of increasing responsibility from April 2015 to December 2023, and was most recently Vice President, Chief Compliance Officer, North America and Global Specialty Care, responsible for compliance across all therapeutic areas from January 2022 to December 2023. Prior to Sanofi, Ms. Kelley was Global Compliance and Commercial Legal Counsel at Boston Scientific from September 2012 to March 2015. Earlier in her career, Ms. Kelley spent ten years in enforcement roles with the U.S. federal government, including as a Trial Attorney for the Department of Justice in Washington, D.C. and an Assistant United States Attorney and Deputy Chief of Litigation for the U.S. Attorney's Office for the District of Massachusetts focused on healthcare matters. Ms. Kelley earned her J.D. from American University Law School and holds a B.S. degree from Georgetown University in Foreign Service.

Dr. Jacqualyn A. Fouse, PhD, Previously served as Chief Executive Officer of Agios Pharmaceuticals, Inc. (Agios), a publicly traded biopharmaceutical company, from February 2019 until her retirement in August 2022, Served as Executive Chair of Dermavant Sciences, Inc, a biopharmaceutical company, from July 2017 to September 2018, Served in various leadership capacities at Celgene Corporation, a biopharmaceutical company, including Strategic Advisor to the Management Executive Committee from April 2017 to June 2017, President and Chief Operating Officer from March 2016 to March 2017, President, Hematology and Oncology from August 2014 to February 2016, Executive Vice President and Chief Financial Officer from February 2012 to July 2014 and Senior Vice President and Chief Financial Officer from September 2010 to February 2012, Chief Financial Officer of Bunge Limited, a global agribusiness and food company, from July 2007 to September 2010, Senior Vice President, Chief Financial Officer and Corporate Strategy at Alcon Laboratories, Inc. from 2006 to 2007 and prior to that, held the position of Senior Vice President and Chief Financial Officer, Held a variety of senior leadership roles with international companies in Europe, including Swiss International Air Lines AG and Nestle S.A. from 2002 to 2006, Dr. Fouse earned a B.A. and M.A. in Economics and a Ph.D. in Finance from The University of Texas at Arlington. Dr. Fouse serves on the board of directors of the following publicly traded companies: Incyte since November 2017, Agios since December 2017

Mr. Daniel J. Brennan, Previously served as Executive Vice President and Chief Financial Officer of Boston Scientific Corporation (Boston Scientific), a medical device and healthcare technology company, from January 2014 until his retirement in June 2025, Was responsible for several company functions at Boston Scientific, including global controllership, global internal audit, corporate finance, treasury, corporate tax, investor relations and corporate business development, Joined Boston Scientific in 1996 and held roles of increasing responsibility within finance, Previously served on the board of directors of Nuance Corporation from September 2018 until March 2022, Mr. Brennan holds a B.S. in Finance and Investments and an M.B.A. from Babson College and is also a certified public accountant. Mr. Brennan has served on the board of directors of Waters Corporation since November 2022.

Mr. Julian C. Baker, Managing Member of Baker Bros. Advisors LP (BBA), a biotechnology-focused investment advisor to fund partnerships whose investors are primarily endowments and foundations. Founded BBA, together with his brother Felix Baker, in 2000. Portfolio manager at Tisch Financial Management from 1994 to 1999, prior to BBA, Employed by the private equity investment arm of Credit Suisse First Boston Corporation from 1988 to 1993. Previously served on the board of directors of Alumis, Inc. from January 2022 to June 2024 and Prelude Therapeutics Inc. (Prelude) from January 2021 to June 2025. Mr. Baker holds an A.B. from Harvard University. Mr. Baker serves on the board of directors of the following publicly traded companies: Incyte Corporation (Incyte) since November 2001, Acadia Pharmaceuticals, Inc. (Acadia) since December 2015, Denali Therapeutics Inc. since June 2025

Dr. Raymond Cheong, M.D., Serves as Managing Director at BBA. , Awarded the Michael A. Shanoff Award for best thesis research within Johns Hopkins University, School of Medicine. , Previously served on the board of directors of Talis Biomedical Corporation from March 2023 to October 2024 and Istari Oncology, Inc. from December 2018 to December 2025. , Dr. Cheong earned his B.S. in Chemical Engineering from the University of Maryland, College Park and completed an M.D. and a Ph.D. in Biomedical Engineering from Johns Hopkins University. Dr. Cheong has served on the board of directors of vTv Therapeutics Inc. since February 2024.

Dr. Richard S. Levy,M.D., Executive Vice President and Chief Drug Development Officer at Incyte from January 2009 until his retirement in April 2016. Previously served as Senior Vice President of Drug Development at Incyte from August 2003 to January 2009. , Vice President, Biologic Therapies, at Celgene from 2002 to 2003. , Served in various executive positions with DuPont Pharmaceuticals Company (DuPont), first as Vice President, Regulatory Affairs and Pharmacovigilance, and thereafter as Vice President, Medical and Commercial Strategy, from 1997 to 2001. , Served in positions of increasing responsibility in clinical research and regulatory affairs at Novartis AG (Novartis), and its predecessor company Sandoz, from 1991 to 1997. , Part-time Senior Advisor for BBA, from December 2016 to May 2019. , Board Certified in Internal Medicine and Gastroenterology and served as Assistant Professor of Medicine at the UCLA School of Medicine from 1989 to 1991. , Previously served on the board of directors of Constellation Pharmaceuticals, Inc. from April 2020 to July 2021. , Dr. Levy received his A.B. in Biology from Brown University and his M.D. from the University of Pennsylvania School of Medicine, and completed his training in Internal Medicine at the Hospital of the University of Pennsylvania and a fellowship in Gastroenterology and Hepatology at UCLA. Dr. Levy serves on the board of directors of the following publicly traded companies: ProTara Therapeutics, Inc. since December 2019 , Kodiak Sciences, Inc. since May 2018 , Kiniksa Pharmaceuticals, Ltd. since March 2019

Mr. James M. Daly, Possesses over 30 years of experience leading U.S. and global businesses in the biopharmaceutical industry. Served as Executive Vice President and Chief Commercial Officer at Incyte from 2012 until his retirement in 2015, Held various leadership positions from 2002 to 2011 at Amgen, Inc., including as Senior Vice President, North America Commercial Operations, Global Marketing and Commercial Development, Spent over 16 years with Glaxo Wellcome/GlaxoSmithKline from 1985 to 2001, where he held roles of increasing responsibility, including as Senior Vice President, General Manager of the Respiratory and Anti-Infective Business Unit. Previously served on the board of directors of Bellicum Pharmaceuticals, Inc. from May 2016 to May 2022 and Halozyme Therapeutics, Inc. from February 2016 to December 2023, Mr. Daly earned a B.S. in Pharmacy and an M.B.A. from the University at Buffalo, The State University of New York. Mr. Daly serves on the board of directors of the following publicly traded companies: Acadia since January 2016, argenx SE since May 2018, Cytokinetics Inc. since August 2025

On August 11, 2026, the Board of Directors of Madrigal Pharmaceuticals, Inc. elected John C. Reed, M.D., Ph.D. to fill the newly created vacancy on the Board effective as of August 11, 2026.

On December 5, 2025, the Board of Directors of Madrigal Pharmaceuticals, Inc. appointed Rita Thakkar as Senior Vice President and Chief Accounting Officer of the Company, effective January 12, 2026. Ms. Thakkar, age 52, was most recently Senior Vice President, Global Business Operations and Capabilities at Bristol Myers Squibb (BMS) since 2024. Ms. Thakkar previously served as Chief Audit Officer at BMS from 2019 and as Vice President, Internal Audit at Celgene Corporation (Celgene) from 2018 until its acquisition by BMS. During her tenure at BMS, Ms. Thakkar oversaw the global audit team and facilitated the enterprise risk management program and chaired the enterprise risk committee. Broadly, Ms. Thakkar has developed an expertise in areas including internal audit, enterprise risk management, finance and controllership. Ms. Thakkar began her career at PricewaterhouseCoopers Canada in various roles and held prior leadership roles at Celgene, CA Technologies (now Broadcom), McKesson Corporation and Kendle International (now Syneos Health). Ms. Thakkar holds a Bachelor of Arts, Honors Chartered Accountancy Studies degree from the University of Waterloo and completed University of Pennsylvania's Executive Leadership Program at the Wharton School of Business. Ms. Thakkar is a Certified Public Accountant and Chartered Professional Accountant (Canada).